IL-15 heterodimeric protein and uses thereof

US10206980B2 · kind B2 · utility

Assignees

• SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. · CN
• JIANGSU HENGRUI MEDICINE CO., LTD. · CN

Inventors

• Xiangdong QU · Shanghai, CN
• Xin Ye · Beijing, CN
• Jijun Yuan · Shanghai, CN
• Lei Zhang · Beijing, CN
• Kan Chen · Shanghai, CN
• Lianshan Zhang · 安丰镇, CN
• Guoqing CAO · 安丰镇, CN
• Zhibin Xu · Shanghai, CN
• Weikang Tao · Shanghai, CN

Key dates

• Filing date: Dec 25, 2014
• Grant date: Feb 19, 2019
• Expiry date: Dec 25, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided is an IL-15 heterodimeric protein, such as an IL-15/IL-15Rα heterodimeric protein. The IL-15 heterodimeric protein contains protein (I) and protein (II). Protein (I) is recombinantly produced by combining IL-15 or a variant thereof with a first Fc variant, and protein (II) is a second Fc variant, or recombinantly produced by combining IL-15Rα or a variant thereof with a second Fc variant. The first Fc variant and the second Fc variant are preferably linked via a “Knob-into-Hole” mode. Also provided are methods of using the IL-15 heterodimeric proteins to modulate an immune response. The provided IL-15 heterodimeric proteins have significant anti-tumor activity, better biological activity and prolonged in vivo half-life compared to the IL-15 molecule alone.